iNtRON Biotechnology Inc (048530) — Cash Flow-to-Debt Ratio
iNtRON Biotechnology Inc (048530) has a Cash Flow-to-Debt Ratio of -0.21x as of September 2025, meaning its operating cash flow of ₩-993.53 Million could theoretically repay 0% of its total liabilities (₩4.73 Billion) in one year. Explore iNtRON Biotechnology Inc (048530) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
iNtRON Biotechnology Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for iNtRON Biotechnology Inc across 11 annual periods. Also explore 048530 asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for iNtRON Biotechnology Inc (2012–2024)
Year-by-year debt coverage analysis for iNtRON Biotechnology Inc. For market capitalisation and broader financial context, see 048530 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | ₩-138.47 Million | ₩2.60 Billion | ▼ -103.2% |
| 2023 | 1.66x | ₩3.12 Billion | ₩1.88 Billion | ▲ +864.7% |
| 2022 | 0.17x | ₩5.98 Billion | ₩34.78 Billion | ▼ -45.7% |
| 2021 | 0.32x | ₩16.47 Billion | ₩52.02 Billion | ▼ -32.7% |
| 2020 | 0.47x | ₩7.13 Billion | ₩15.16 Billion | ▲ +1493.7% |
| 2019 | -0.03x | ₩-812.48 Million | ₩24.07 Billion | ▼ -112.6% |
| 2018 | 0.27x | ₩4.20 Billion | ₩15.70 Billion | ▲ +175.3% |
| 2017 | -0.36x | ₩-5.47 Billion | ₩15.38 Billion | ▲ +20.0% |
| 2016 | -0.44x | ₩-4.64 Billion | ₩10.46 Billion | ▼ -255.0% |
| 2015 | 0.29x | ₩1.70 Billion | ₩5.93 Billion | ▲ +768.1% |
| 2012 | -0.04x | ₩-331.01 Million | ₩7.72 Billion | — |